153 related articles for article (PubMed ID: 37862969)
21. Cucurbitacin IIa interferes with EGFR-MAPK signaling pathway leads to proliferation inhibition in A549 cells.
Zhang J; Song Y; Liang Y; Zou H; Zuo P; Yan M; Jing S; Li T; Wang Y; Li D; Zhang T; Wei Z
Food Chem Toxicol; 2019 Oct; 132():110654. PubMed ID: 31265865
[TBL] [Abstract][Full Text] [Related]
22. Polymeric micelles for the solubilization and delivery of STAT3 inhibitor cucurbitacins in solid tumors.
Molavi O; Ma Z; Mahmud A; Alshamsan A; Samuel J; Lai R; Kwon GS; Lavasanifar A
Int J Pharm; 2008 Jan; 347(1-2):118-27. PubMed ID: 17681440
[TBL] [Abstract][Full Text] [Related]
23. Anticancer activity of cucurbitacin-A in ovarian cancer cell line SKOV3 involves cell cycle arrest, apoptosis and inhibition of mTOR/PI3K/Akt signaling pathway.
Liu J; Liu X; Ma W; Kou W; Li C; Zhao J
J BUON; 2018; 23(1):124-128. PubMed ID: 29552771
[TBL] [Abstract][Full Text] [Related]
24. Cucurbitacin IIa: a novel class of anti-cancer drug inducing non-reversible actin aggregation and inhibiting survivin independent of JAK2/STAT3 phosphorylation.
Boykin C; Zhang G; Chen YH; Zhang RW; Fan XE; Yang WM; Lu Q
Br J Cancer; 2011 Mar; 104(5):781-9. PubMed ID: 21304528
[TBL] [Abstract][Full Text] [Related]
25. Cucurbitacin IIb from Ibervillea sonorae Induces Apoptosis and Cell Cycle Arrest via STAT3 Inhibition.
Torres-Moreno H; Marcotullio MC; Velazquez C; Arenas-Luna VM; Hernández-Gutiérrez S; Robles-Zepeda RE
Anticancer Agents Med Chem; 2020; 20(10):1188-1196. PubMed ID: 32294048
[TBL] [Abstract][Full Text] [Related]
26. Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity.
Sun J; Blaskovich MA; Jove R; Livingston SK; Coppola D; Sebti SM
Oncogene; 2005 May; 24(20):3236-45. PubMed ID: 15735720
[TBL] [Abstract][Full Text] [Related]
27. Cucurbitacin-B inhibits neuroblastoma cell proliferation through up-regulation of PTEN.
Shang Y; Guo XX; Li WW; Rao W; Chen ML; Mu LN; Li SJ
Eur Rev Med Pharmacol Sci; 2014; 18(21):3297-303. PubMed ID: 25487942
[TBL] [Abstract][Full Text] [Related]
28. Cucurbitacin-I, a natural cell-permeable triterpenoid isolated from Cucurbitaceae, exerts potent anticancer effect in colon cancer.
Kim HJ; Park JH; Kim JK
Chem Biol Interact; 2014 Aug; 219():1-8. PubMed ID: 24858077
[TBL] [Abstract][Full Text] [Related]
29. Structural optimization and biological screening of a steroidal scaffold possessing cucurbitacin-like functionalities as B-Raf inhibitors.
Ahmed MS; Kopel LC; Halaweish FT
ChemMedChem; 2014 Jul; 9(7):1361-7. PubMed ID: 24682977
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and biological studies of c(RGDyK) conjugates of cucurbitacins.
Chatzisideri T; Dalezis P; Leonidis G; Bousis S; Trafalis D; Bianchini F; Sarli V
Future Med Chem; 2021 May; 13(10):877-895. PubMed ID: 33858195
[TBL] [Abstract][Full Text] [Related]
31. Cucurbitacins - a promising target for cancer therapy.
Alghasham AA
Int J Health Sci (Qassim); 2013 Jan; 7(1):77-89. PubMed ID: 23559908
[TBL] [Abstract][Full Text] [Related]
32. Cucurbitacin-E inhibits multiple cancer cells proliferation through attenuation of Wnt/β-catenin signaling.
Feng H; Zang L; Zhao ZX; Kan QC
Cancer Biother Radiopharm; 2014 Jun; 29(5):210-4. PubMed ID: 24885795
[TBL] [Abstract][Full Text] [Related]
33. [Preparation of cucurbitacin compounds in
Sun J; Sun J; Li H; Yan X; Li D; Lu F
Se Pu; 2022 Apr; 40(4):364-371. PubMed ID: 35362684
[TBL] [Abstract][Full Text] [Related]
34. Isolation of anticancer constituents from Cucumis prophetarum var. prophetarum through bioassay-guided fractionation.
Alsayari A; Kopel L; Ahmed MS; Soliman HSM; Annadurai S; Halaweish FT
BMC Complement Altern Med; 2018 Oct; 18(1):274. PubMed ID: 30301463
[TBL] [Abstract][Full Text] [Related]
35. Cucurbitacin B inhibits human breast cancer cell proliferation through disruption of microtubule polymerization and nucleophosmin/B23 translocation.
Duangmano S; Sae-Lim P; Suksamrarn A; Domann FE; Patmasiriwat P
BMC Complement Altern Med; 2012 Oct; 12():185. PubMed ID: 23062075
[TBL] [Abstract][Full Text] [Related]
36. Use of cucurbitacins for lung cancer research and therapy.
Liu M; Yan Q; Peng B; Cai Y; Zeng S; Xu Z; Yan Y; Gong Z
Cancer Chemother Pharmacol; 2021 Jul; 88(1):1-14. PubMed ID: 33825035
[TBL] [Abstract][Full Text] [Related]
37. Chemical modification produces species-specific changes in cucurbitacin antifeedant effect.
Lang KL; Deagosto E; Zimmermann LA; Machado VR; Campos Bernardes LS; Schenkel EP; Duran FJ; Palermo J; Rossini C
J Agric Food Chem; 2013 Jun; 61(23):5534-9. PubMed ID: 23646892
[TBL] [Abstract][Full Text] [Related]
38. Cucurbitacins inspired organic synthesis: Potential dual inhibitors targeting EGFR - MAPK pathway.
Mahnashi M; Elgazwi SM; Ahmed MS; Halaweish FT
Eur J Med Chem; 2019 Jul; 173():294-304. PubMed ID: 31022583
[TBL] [Abstract][Full Text] [Related]
39. The cucurbitacins E, D and I: investigation of their cytotoxicity toward human chondrosarcoma SW 1353 cell line and their biotransformation in man liver.
Abbas S; Vincourt JB; Habib L; Netter P; Greige-Gerges H; Magdalou J
Toxicol Lett; 2013 Feb; 216(2-3):189-99. PubMed ID: 23194827
[TBL] [Abstract][Full Text] [Related]
40. Multivariate SAR and QSAR of cucurbitacin derivatives as cytotoxic compounds in a human lung adenocarcinoma cell line.
Lang KL; Silva IT; Machado VR; Zimmermann LA; Caro MS; Simões CM; Schenkel EP; Durán FJ; Bernardes LS; de Melo EB
J Mol Graph Model; 2014 Mar; 48():70-9. PubMed ID: 24378396
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
